Back to results
US 10,420,789 B2Granted
Methods and compositions for the activation of gamma-delta T-cells
AssigneeAmerican Gene Technologies International Inc.
InventorsCharles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
Claims20
A pharmaceutical combination, comprising:
- (a) a bisphosphonate drug;
- and
- (b) a lentiviral particle comprising an envelope protein and:
- (i) at least one encoded shRNA capable of inhibiting production of farnesyl diphosphate synthase, or
- (ii) at least one encoded microRNA capable of inhibiting production of farnesyl diphosphate synthase.
2 more elements
A pharmaceutical combination, comprising:
- (a) a bisphosphonate drug;
- (b) at least one helper plasmid comprising sequences that encode gag, pol, and rev genes;
- (c) an envelope plasmid comprising a sequence that encodes an envelope gene;
- and
- (d) a therapeutic vector comprising:
- (i) at least one sequence that encodes a shRNA capable of inhibiting production of farnesyl diphosphate synthase, or
- (ii) at least one sequence that encodes a microRNA capable of inhibiting production of farnesyl diphosphate synthase.
4 more elements
A pharmaceutical combination, comprising:
- (a) a bisphosphonate drug;
- and
- (b) an immunotherapy-based viral delivery system, comprising:
- (i) at least one helper plasmid comprising sequences that encode gag, pol, and rev genes;
- (ii) an envelope plasmid comprising a sequence that encodes an env gene;
- and
- (iii) a therapeutic vector comprising:
- at least one encoded shRNA capable of inhibiting production of farnesyl diphosphate synthase, or
- at least one encoded microRNA capable of inhibiting production of farnesyl diphosphate synthase.
6 more elements
Dependencies are inferred from the claim text.